Figure 4.
Progression-free survival in 553 patients in the intention-to-treat population, by treatment group
Patients still on treatment at the time of trial closure and treatment crossover were censored. EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.